Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 7/20 | 0.49 |
| ▸ | UGT1A4 | P22310 | 1/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28381262 | 0.83 | CYP19A1 (0.51) | CYP19A1UGT1A4PDE4DESR1ESR2 | |
| SCHEMBL13265761 | 0.81 | CYP19A1 (0.54) | CYP19A1UGT1A4PDE4DESR1ESR2 | |
| SCHEMBL2258695 | 0.79 | CYP19A1 (0.49) | CYP19A1UGT1A4PDE4DESR1ESR2 | |
| SCHEMBL16527234 | 0.79 | ESR1 (0.42) | CYP19A1UGT1A4PDE4DESR1ESR2 | |
| SCHEMBL8072845 | 0.79 | CYP19A1 (0.49) | CYP19A1UGT1A4PDE4DESR1ESR2 | |
| SCHEMBL3173073 | 0.79 | CYP19A1 (0.49) | CYP19A1UGT1A4PDE4DESR1ESR2 | |
| SCHEMBL12123247 | 0.79 | CYP19A1 (0.49) | CYP19A1UGT1A4PDE4DESR1ESR2 | |
| SCHEMBL936470 | 0.79 | CYP19A1 (0.49) | CYP19A1UGT1A4PDE4DESR1ESR2 | |
| SCHEMBL8069078 | 0.76 | CYP19A1 (0.46) | CYP19A1UGT1A4PDE4D | |
| SCHEMBL16238250 | 0.76 | CYP19A1 (0.46) | CYP19A1UGT1A4PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207915-A1 | Process for the Preparation of 2,2'-[5-(1H-1,2,4-Triazole-1-Ylmethyl) -1,3-Phenylene] Di (2-Methylpropionitrile) | USV LIMITED (IN) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207915-A1 | Process for the Preparation of 2,2'-[5-(1H-1,2,4-Triazole-1-Ylmethyl) -1,3-Phenylene] Di (2-Methylpropionitrile) | CYP19A1, CYP11A1, HCN2 | CYP19A1 1/4885UGT1A4 2895/4885PDE4D 3218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.